


### Amendments to the Claims


This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Original) A compound of formula I






Formula I


wherein:



is a 6,5-bicyclic ring selected from the group consisting of:




and




$R^1$  is selected from the group consisting of:

- (a) hydrogen,
- (b) alkylcarbonyl optionally substituted with heterocyclyl,
- (c) heterocyclylcarbonyl optionally substituted with alkyl or acetyl,
- (d) alkyl or haloalkyl,
- (e) cycloalkyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, oxo, hydroxy, alkoxy, amino, alkylamino and dialkylamino,
- (f) heterocyclyl selected from the group consisting of:



(g) aryl optionally substituted with halo, alkyl, alkoxy, cyano, amino, alkylamino or dialkylamino, and

(h) heteroaryl selected from the group consisting of:



$R^2$  is hydrogen, alkyl, heterocyclyl or, together with  $R^1$  and the carbon to which they are attached, forms a saturated ring substituent selected from the group consisting of:

(a) cycloalkyl, and

(b) heterocyclyl selected from the group consisting of:

tetrahydrofuryl, tetrahydropyranyl and piperidinyl optionally substituted with alkyl, acetyl or aryl,

$X$  is  $-NR^{13}R^3$  or


$R^3$  is selected from the group consisting of:

(a) hydrogen,


(b) alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, alkoxy, halogen, amino, alkylamino and dialkylamino,

(c) cycloalkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, alkoxy, halo, amino, alkylamino and dialkylamino,


(d) heterocyclyl selected from the group consisting of:




(e) cycloalkylalkyl selected from the group consisting of:




(f) heterocyclylalkyl selected from the group consisting of:




(g) arylalkyl selected from the group consisting of




(h) heteroarylalkyl selected from the group consisting of:





is a heterocyclic ring selected from the group consisting of:




$R^4$  is hydrogen, phenyl, halophenyl, acyl or alkoxycarbonyl;

$R^5$  is hydrogen, hydroxy or alkoxy;

each of  $R^6$  and  $R^7$  is independently selected from hydrogen, halo, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, alkoxycarbonyl, dialkylaminocarbonyl, aryl and aryloxy;

$R^8$  is hydrogen, hydroxyalkyl, acyl, oxo, aryl, pyridinyl, alkyl-SO<sub>2</sub>-O-,  $R^b$ -NH-CH<sub>2</sub>- , arylalkyl, or  $R^c$ N-CO-O- ;

$R^9$  is hydrogen, hydroxy, hydroxyalkyl, acyl, halo, dihalo, oxo, aryl, haloaryl-CH<sub>2</sub>-,



pyridinyl, alkyl-SO<sub>2</sub>-O-,  $R^a$ -NH-,  $R^b$ -NH-CH<sub>2</sub>- , arylalkyl, or  $R^c$ N-CO-O-;

$R^{10}$  is hydrogen, alkyl, alkoxycarbonyl, aryl or haloaryl;

$R^{11}$  is hydrogen, alkyl or aryl;

$R^{12}$  is hydrogen or aryl;

$R^{13}$  is hydrogen or alkyl;

$R^{14}$  is hydrogen, alkyl, aryl or acyl;

$R^a$  is hydrogen, alkoxycarbonyl or halophenyl;

$R^b$  is hydrogen, alkoxy, phenyl, halophenyl, halophenylalkyl, halopyridinyl, pyrimidinyl, alkoxycarbonyl, dialkylaminocarbonyl, or dialkylaminothiocarbonyl; and


$R^c$  is hydrogen or alkyl;

and all salts, solvates, optical and geometric isomers, and crystalline forms thereof and with the proviso that the compound of formula (I) is other than [4-(2,3-dihydro-indole-1-sulfonyl)-phenyl]- (4-phenyl-piperazin-1-yl)-methanone,


[4-(2,3-dihydro-indole-1-sulfonyl)-phenyl]-morpholin-4-yl-methanone, and  
[4-(2,3-dihydro-indole-1-sulfonyl)-phenyl]-piperidin-1-yl-methanone.

2. (Cancelled)

3. (Currently amended) The compound of Claim 1 or ~~Claim 2~~, wherein:




is a 6,5-bicyclic ring selected from the group consisting of:




$R^1$  is selected from the group consisting of:

- (a) hydrogen,
- (b) alkylcarbonyl optionally substituted with heterocyclyl,
- (c) heterocyclylcarbonyl optionally substituted with alkyl or acetyl,
- (d) methyl, propyl, t-butyl or trifluoromethyl,
- (e) cycloalkyl optionally substituted with oxo, hydroxy, methoxy, difluoro or methyl,
- (f) heterocyclyl selected from the group consisting of:



- (g) phenyl optionally substituted with halo, methyl, methoxy, cyano or dimethylamino, and

- (h) heteroaryl selected from the group consisting of:




$R^2$  is hydrogen, methyl, ethyl, or together with  $R^1$  and the carbon to which they are attached, forms a saturated ring substituent selected from the group consisting of:

- (a) cycloalkyl, and
  - (b) heterocyclyl selected from the group consisting of: tetrahydropyranyl, and N-methylpiperidin-4-yl;


X is  $-\text{NR}^1\text{R}^2\text{R}^3$  or

$R^3$  is selected from the group consisting of:



- (a) hydrogen,
  - (b) ( $C_1$ - $C_2$ ) alkyl optionally substituted with ( $C_1$ - $C_2$ ) alkoxy,
  - (c) ( $C_4$ - $C_6$ ) cycloalkyl optionally substituted with one or two substituents independently selected from hydroxy, methoxy, amino, alkylamino, and dialkylamino;
  - (d) heterocyclyl selected from the group consisting of:



- (e) cycloalkylalkyl selected from the group consisting of:





- (f) heterocyclalkyl selected from the group consisting of:





(g) arylalkyl which is ; and

(h) heteroarylalkyl selected from the group consisting of:



is a heterocyclic ring selected from the group consisting of:

 $R^4$  is hydrogen, phenyl, fluorophenyl, t-butyloxycarbonyl or methoxycarbonyl; $R^5$  is hydrogen, hydroxy or methoxy;each of  $R^6$  and  $R^7$  is independently selected from the group consisting of hydrogen, alkyl, fluoro, chloro, trifluoromethyl, cyano, methoxy, amino, monomethylamino, dimethylamino, methoxycarbonyl and dimethylaminocarbonyl; $R^8$  is hydrogen, hydroxyalkyl, acyl, oxo, aryl, pyridinyl, alkyl-SO<sub>2</sub>-O-,  $R^b$ -NH-CH<sub>2</sub>-, arylalkyl or (CH<sub>3</sub>)<sub>2</sub>N-CO-O-; $R^9$  is hydrogen, hydroxy, hydroxymethyl, acetyl, fluoro, difluoro, oxo, phenyl, benzyl,pyridinyl, CH<sub>3</sub>-SO<sub>2</sub>-O-,  $R^a$ -NH-,  $R^b$ -NH-CH<sub>2</sub>- , , or (CH<sub>3</sub>)<sub>2</sub>N-CO-O-; $R^{10}$  is hydrogen or alkyl;

R<sup>11</sup> is hydrogen or alkyl;

R<sup>12</sup> is hydrogen or phenyl;


R<sup>13</sup> is hydrogen or methyl;

R<sup>14</sup> is hydrogen, methyl, phenyl or acetyl;

R<sup>a</sup> is hydrogen, methoxycarbonyl, t-butyloxycarbonyl or fluorophenyl; and

R<sup>b</sup> is hydrogen, methoxy, phenyl, phenylalkyl, fluorophenylalkyl, fluorophenyl, pyridinyl, fluoropyridinyl, pyrimidinyl, methoxycarbonyl, t-butyloxycarbonyl, dimethylaminocarbonyl or dimethylaminothiocarbonyl.

4. (Cancelled)



6. (Cancelled).

7. (Currently amended) The compound of Claim 4,~~5, or 6~~, wherein R<sup>1</sup> is aryl optionally substituted with halo, alkyl, alkoxy, cyano, amino, alkylamino or dialkylamino.

8. (Original) The compound of Claim 7, wherein R<sup>1</sup> is phenyl.

9. (Currently amended) The compound of Claim 4,~~5, or 6~~, wherein R<sup>1</sup> is cycloalkyl optionally substituted with one or two substituents independently selected from the group consisting of alkyl, halo, oxo, hydroxy, alkoxy, amino, alkylamino and dialkylamino.

10. (Original) The compound of Claim 9, wherein R<sup>1</sup> is cyclopentyl.

11. (Cancelled).

12. (Cancelled).

13. (Cancelled).

14. (Cancelled).

15. (Cancelled).

16. (Cancelled).



17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (Cancelled).

21. (Currently amended) The compound of ~~any one of~~ according to Claims 1 to 12, wherein R<sup>3</sup> is arylalkyl selected from the group consisting of:



22. (Original) The compound of Claim 21, wherein R<sup>3</sup> is

23. (Cancelled).

24. (Cancelled).

25. (Currently amended) A compound according to any one of Claims 1 to 24, selected from the group consisting of: wherein the compound is:

N-(4-Fluoro-benzyl)-4-(3-phenyl-indole-1-sulfonyl)-benzamide,

N-(5-Fluoro-pyridin-3-ylmethyl)-4-(3-phenyl-indole-1-sulfonyl)-benzamide,

4-(3-Phenyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-ylmethyl)-benzamide,

4-(3-Cyclopentyl-indole-1-sulfonyl)-N-(4-fluoro-benzyl)-benzamide,  
N-(4-Fluoro-benzyl)-4-[3-(tetrahydro-pyran-4-yl)-indole-1-sulfonyl]-benzamide,  
N-Cyclopropylmethyl-4-(3-phenyl-indole-1-sulfonyl)-benzamide,  
4-(3-Cyclopentyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-yl)-benzamide, or  
4-(3-Cyclopentyl-indole-1-sulfonyl)-N-(tetrahydro-pyran-4-ylmethyl)-benzamide.

26. (Currently amended) A compound according to ~~any one~~ of Claims 1 to 25, wherein the compound is:

4-(3-Cyclopentyl-indole-1-sulfonyl)-N-(4-fluoro-benzyl)-benzamide.

27. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any one~~ of claims 1 to 26 or ~~[4 (2,3 dihydro indole 1 sulfonyl) phenyl] (4 phenyl piperazin 1 yl) methanone, [4 (2,3 dihydro indole 1 sulfonyl) phenyl] morpholin 4 yl methanone, or~~ ~~[4 (2,3 dihydro indole 1 sulfonyl) phenyl] piperidin 1 yl methanone~~ in an amount effective to antagonize CB-1 receptor stimulation, and a pharmaceutically acceptable carrier, diluent or excipient.

28. (Cancelled).

29. (Cancelled).

30. (Currently amended) A method for treating a condition which is treatable by reducing CB-1 receptor stimulation, comprising, administering to a mammal in need thereof ~~a composition according to any one of Claims 27, 28 or 29 an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof.~~

31. (Original) The method of Claim 30, wherein the mammal is a human.

32. (Currently amended) The method of Claim 30 or ~~Claim 31~~, wherein the condition is ~~psychosis, memory deficit, cognitive disorder, migraine, neuropathy, neuroinflammatory disorder, cerebral vascular accident, head trauma, anxiety disorder, stress, depression, epilepsy, Parkinson's disease, schizophrenia, substance abuse disorder, obesity, or an eating disorder associated with excessive food intake.~~

33. (Original) The method of Claim 32, wherein the condition is obesity.
34. (Cancelled).
35. (Cancelled).
36. (Cancelled).
37. (Cancelled).
38. (Cancelled).
39. (Cancelled).
40. (Cancelled).
41. (Cancelled).
42. (Cancelled).
43. (Cancelled).
44. (Cancelled).
45. (New) A compound according to claim 25, wherein the compound is N-(4-Fluorobenzyl)-4-(3-phenyl-indole-1-sulfonyl)-benzamide.